10x Genomics $TXG Stock Position Raised by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS Asset Management raised its stake in 10x Genomics by 235.6% in Q1, owning 5.81% of the company with holdings worth $62 million after acquiring nearly 5 million shares.
• The company reported $0.28 earnings per share, significantly beating analysts' expectations of a loss, and its revenue increased by 12.9% year-over-year to $172.91 million.
• Institutional investors hold 84.68% of 10x Genomics' stock, indicating strong confidence in the company, though recent analyst ratings vary from "buy" to "sell."

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 235.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,103,768 shares of the company's stock after buying an additional 4,987,195 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 5.81% of 10x Genomics worth $62,016,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TXG. Cetera Investment Advisers boosted its stake in 10x Genomics by 22.7% during the 4th quarter. Cetera Investment Advisers now owns 19,898 shares of the company's stock valued at $286,000 after purchasing an additional 3,679 shares during the period. Deutsche Bank AG boosted its stake in 10x Genomics by 35.3% during the 4th quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock valued at $146,000 after purchasing an additional 2,657 shares during the period. Gotham Asset Management LLC acquired a new position in 10x Genomics during the 4th quarter valued at about $264,000. Jacobs Levy Equity Management Inc. acquired a new position in 10x Genomics during the 4th quarter valued at about $450,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in 10x Genomics by 37.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,165 shares of the company's stock valued at $2,286,000 after purchasing an additional 42,950 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Stock Performance

10x Genomics stock opened at $12.64 on Monday. The firm has a market cap of $1.57 billion, a PE ratio of -18.06 and a beta of 2.00. The firm's 50 day moving average price is $13.21 and its two-hundred day moving average price is $10.81. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $24.38.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. The firm had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Equities analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on TXG shares. Piper Sandler started coverage on shares of 10x Genomics in a research note on Thursday. They set a "neutral" rating and a $15.00 target price for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, August 30th. Zacks Research lowered shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 5th. Morgan Stanley reduced their price target on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Finally, UBS Group upped their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $13.65.

Insiders Place Their Bets

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider directly owned 440,888 shares of the company's stock, valued at $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Adam Taich sold 22,315 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares of the company's stock, valued at $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 39,149 shares of company stock valued at $539,865 over the last ninety days. Corporate insiders own 10.03% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.